Whalesbook
Pharma Stock Reaches New Peak
Sai Life Sciences shares surged to an all-time high of ₹966.10 on Monday, gaining 5% on the BSE during intra-day trading. This rally was fueled by strong expectations of healthy earnings and follows a period of significant growth for the Hyderabad-based pharmaceutical company. The stock's ascent occurred even as the broader BSE Sensex saw a marginal dip of 0.02% at the time of reporting.
Robust Financial Performance
The company, a Contract Research, Development & Manufacturing Organization (CRDMO), reported impressive financial results for the first half of fiscal year 2025-26 (H1FY26). Total revenue climbed 53% year-on-year to ₹1,034 crore, driven by robust performance in both its Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) businesses. EBITDA margins saw a substantial improvement of 650 basis points, reaching 27%, attributed to better asset utilization and cost discipline.
The CDMO segment, which contributes 64% to total revenue, posted a 72% year-on-year growth, reaching ₹667 crore. This expansion is supported by the continuous scale-up of late-stage and commercial programs. Sai Life Sciences is further enhancing its capabilities by increasing its total installed capacity from 700 KL to 1150 KL by the end of FY27. Management highlighted a focus on improving asset productivity and optimizing working capital.
Sector Tailwinds Fuel Growth
Sai Life Sciences operates in the burgeoning CRDMO industry, which is experiencing significant global tailwinds. Indian CRDMOs are gaining prominence, benefiting from increased outsourcing by global pharmaceutical and biotech clients seeking cost-efficient, high-quality partners. The small molecule CRDMO industry in India is projected to grow substantially, with an estimated market size of $12.8 billion by 2028, growing at a compound annual growth rate (CAGR) of 13.7%.
Analyst Optimism
Analysts at JM Financial Institutional Equities view the Indian CRDMO sector as entering a sustained growth phase. They anticipate leading listed players to achieve a 17% revenue CAGR over FY25-28. This optimistic outlook is driven by recurrent contract wins, new client additions, capacity expansions, and the adoption of advanced technologies. JM Financial has issued a 'BUY' rating on Sai Life Sciences with a target price of ₹1,197 per share, projecting it as the fastest-growing CRDMO in India, with the CDMO segment expected to grow at a 26% CAGR over FY25–28.